Clinical development of farnesyltransferase inhibitors in leukemias and myelodysplastic syndrome
R Kurzrock, J Cortes, H Kantarjian - Seminars in hematology, 2002 - Elsevier
Farnesyltransferase inhibitors (FTIs) target multiple pathways including the Ras pathway
implicated in the pathogenesis of some hematologic malignancies. R115777 and BMS-
214662, selective FTIs in clinical development, exhibit preclinical activity against cell lines
and tumor xenografts with or without ras mutations. Phase I dose-escalating trials at MD
Anderson Cancer Center have explored the potential of these agents as monotherapy for
leukemias and myelodysplastic syndrome (MDS). In 20 patients with MDS, two cycles of oral …
implicated in the pathogenesis of some hematologic malignancies. R115777 and BMS-
214662, selective FTIs in clinical development, exhibit preclinical activity against cell lines
and tumor xenografts with or without ras mutations. Phase I dose-escalating trials at MD
Anderson Cancer Center have explored the potential of these agents as monotherapy for
leukemias and myelodysplastic syndrome (MDS). In 20 patients with MDS, two cycles of oral …